Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12-9919-41 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-CD178 (Fas Ligand) Monoclonal Antibody (NOK-1), PE, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The NOK-1 monoclonal antibody reacts with human Fas (CD95) Ligand, a 40 kDa type II transmembrane glycoprotein. FasL is a member of the TNF family and is expressed by neutrophils, monocytes, and activated T cells and NK cells. The interaction of FasL with its receptor (CD95, Fas) induces Fas-mediated killing of lymphocytes. Human FasL is cleaved from the surface by matrix metalloproteinases (MMPs), resulting in a 26 kDa soluble form. Therefore for optimal detection of surface FasL on activated peripheral blood cells, incubation of cells with an MMP inhibitor is recommended. Applications Reported: NOK-1 has been reported for use in flow cytometric analysis. Applications Tested: This NOK-1 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Yellow dye
- Isotype
- IgG
- Antibody clone number
- NOK-1
- Vial size
- 25 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Transmembrane TNF-α promotes activation-induced cell death by forward and reverse signaling.
Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection.
Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel.
Siva-1 negatively regulates NF-kappaB activity: effect on T-cell receptor-mediated activation-induced cell death (AICD).
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death.
Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing.
Expression of the functional soluble form of human fas ligand in activated lymphocytes.
Metalloproteinase-mediated release of human Fas ligand.
Zhang M, Wang J, Jia L, Huang J, He C, Hu F, Yuan L, Wang G, Yu M, Li Z
Oncotarget 2017 Sep 8;8(38):63799-63812
Oncotarget 2017 Sep 8;8(38):63799-63812
Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection.
Hu X, Jiang Y, Li X, Gao Y, Guo X, Chi X, Yan H, Feng J, Zhong J, Sun B, Shao X, Xiao W, Pan Y, Niu J
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2014 May;34(5):366-75
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2014 May;34(5):366-75
Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel.
Symes JC, Kurin M, Fleshner NE, Medin JA
Molecular cancer therapeutics 2008 Sep;7(9):3018-28
Molecular cancer therapeutics 2008 Sep;7(9):3018-28
Siva-1 negatively regulates NF-kappaB activity: effect on T-cell receptor-mediated activation-induced cell death (AICD).
Gudi R, Barkinge J, Hawkins S, Chu F, Manicassamy S, Sun Z, Duke-Cohan JS, Prasad KV
Oncogene 2006 Jun 8;25(24):3458-62
Oncogene 2006 Jun 8;25(24):3458-62
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death.
Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L, Johnston PG
Oncogene 2006 Feb 9;25(6):838-48
Oncogene 2006 Feb 9;25(6):838-48
Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing.
Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S
The Journal of experimental medicine 1997 Dec 15;186(12):2045-50
The Journal of experimental medicine 1997 Dec 15;186(12):2045-50
Expression of the functional soluble form of human fas ligand in activated lymphocytes.
Tanaka M, Suda T, Takahashi T, Nagata S
The EMBO journal 1995 Mar 15;14(6):1129-35
The EMBO journal 1995 Mar 15;14(6):1129-35
Metalloproteinase-mediated release of human Fas ligand.
Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H
The Journal of experimental medicine 1995 Dec 1;182(6):1777-83
The Journal of experimental medicine 1995 Dec 1;182(6):1777-83
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Surface staining of human FasL tranfected cells with Anti-Human CD178 (CD95 Ligand) PE. Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.
- Conjugate
- Yellow dye